Thursday, February 4, 2016
Sunnyvale, Calif.-based Clinovo has moved forward with global expansion of its CRO Partner Program utilizing ClinCapture, the next-generation electronic data capture (EDC) software for CROs. Ten new CRO partners have been added in the United States, Russia, Spain, Mexico, India, and Japan. [Read More]
Global CRO ClinTec International has expanded with a Regional Hub Office for Sub-Saharan Africa in Johannesburg, South Africa. Aligning with new client partnerships, the office will support region wide clinical research services including a significant new clinical FSP assignment with a global biotechnology major where ClinTec is the sole FSP partner for South Africa.
Synergy Research Group, a CRO based in Moscow, Russia, is addressing one of the most common roadblocks to clinical trial ramp-up by taking sales and business development out of the proposal and/or bid cycle. This is another step in Synergy’s commitment to offer quality, speed and lower cost to every sponsor.
Synthetic Biologics, a biotechnology company developing novel anti-infective biologics and drugs targeting specific pathogens that cause serious infections and diseases, has expanded its Clinical Advisory Board (CAB) created to support development of SYN-010, the company’s statin-class candidate intended to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS).
The number of new studies approved in Russia during the third quarter of 2011 reached last year’s level, with the Ministry of Health and Social Development of the Russian Federation (MoH) approving 132 new clinical trials of all types, including local and bioequivalence studies, according to Synergy Research Group (SynRG), a Russia-based CRO. That’s only two trials below the number approved in the year-ago quarter.
The number of investigative sites that have been re-accredited by the Russian Ministry of Health (MoH)—a requirement inherent in the country’s new regulations—is now up to almost 600, according to the Association of Clinical Trials Organizations (ACTO), a trade group for those working in research in Russia.
The Ministry of Health and Social Development of the Russian Federation (MoH) approved 95 new clinical trials of all types including local studies during the first quarter of 2011, 29% less than the year-ago quarter, according to a quarterly analytical report produced by Moscow-based CRO Synergy Research Group (SynRG).
According to Russia-based contract research organization (CRO) Synergy Research Group’s Annual Orange Report, Russia’s regulatory agency Federal Service on Surveillance in Healthcare and Social Development of the Russian Federation (RosZdravNadzor, RZN) approved 577 new clinical trials during 2009, 6% fewer than in 2008. Sixty percent, or 348 of the new studies, were multinational multi-center trials, down 4% from 2008.